P2RX7 and graft versus host disease: Regardless of the reasons for the lack of improvement in clinical GVHD by PTCy with BBG compared to PTCy alone, this study reveals that P2X7 antagonism does not mitigate the efficacy of PTCy, keeping open the possibility that this combined treatment may be of value to prevent GVHD, especially liver GVHD, in patients following alloHSCT.